Egetis Therapeutics AB (publ) Cash Flow-to-Debt Ratio
Egetis Therapeutics AB (publ) cash flow-to-debt ratio. Egetis Therapeutics AB (publ) (EGTX) has a Cash Flow-to-Debt Ratio of -0.22x as of March 2026, meaning its operating cash flow of Skr-64.30 Million could theoretically repay 0% of its total liabilities (Skr288.70 Million) in one year. Check EGTX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Egetis Therapeutics AB (publ) (2010–2025)
Cash flow-to-debt ratio of Egetis Therapeutics AB (publ) from 2010 to 2025. Historical debt coverage capacity for Egetis Therapeutics AB (publ) across 16 annual periods. Check EGTX cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Egetis Therapeutics AB (publ) Cash Flow-to-Debt Ratio by Year (2010–2025)
Egetis Therapeutics AB (publ) cash flow-to-debt ratio by year from 2010 to 2025. Year-by-year debt coverage analysis for Egetis Therapeutics AB (publ). For the full cash flow conversion analysis, see Egetis Therapeutics AB (publ) operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.89x | Skr-267.10 Million | Skr300.40 Million | ▼ -16.8% |
| 2024 | -0.76x | Skr-227.90 Million | Skr299.40 Million | ▲ +41.3% |
| 2023 | -1.30x | Skr-278.40 Million | Skr214.60 Million | ▲ +59.0% |
| 2022 | -3.16x | Skr-173.50 Million | Skr54.90 Million | ▼ -2.6% |
| 2021 | -3.08x | Skr-130.11 Million | Skr42.23 Million | ▼ -504.9% |
| 2020 | -0.51x | Skr-134.64 Million | Skr264.34 Million | ▲ +79.5% |
| 2019 | -2.49x | Skr-62.64 Million | Skr25.20 Million | ▲ +29.8% |
| 2018 | -3.54x | Skr-80.31 Million | Skr22.68 Million | ▲ +52.3% |
| 2017 | -7.42x | Skr-86.55 Million | Skr11.66 Million | ▼ -41.3% |
| 2016 | -5.25x | Skr-36.12 Million | Skr6.87 Million | ▲ +55.5% |
| 2015 | -11.82x | Skr-51.15 Million | Skr4.33 Million | ▼ -265.8% |
| 2014 | -3.23x | Skr-41.38 Million | Skr12.81 Million | ▲ +53.3% |
| 2013 | -6.92x | Skr-28.07 Million | Skr4.06 Million | ▼ -41.1% |
| 2012 | -4.90x | Skr-31.96 Million | Skr6.52 Million | ▼ -32.6% |
| 2011 | -3.70x | Skr-14.40 Million | Skr3.89 Million | ▼ -104.5% |
| 2010 | -1.81x | Skr-2.72 Million | Skr1.50 Million | — |